Inquiry Basket
Loading ......
Patritumab deruxtecan (HER3-DXd) is a novel antibody-drug conjugate (ADC) comprising a fully human anti-HER3 monoclonal antibody covalently linked to a potent topoisomerase I inhibitor payload (DXd) via a stable, enzyme-cleavable tetrapeptide linker. This ADC is designed to selectively deliver cytotoxic chemotherapy to HER3-expressing tumor cells, leveraging the specificity of the antibody component to target HER3—a member of the EGFR family of receptor tyrosine kinases that is frequently overexpressed in non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer, among other solid tumors. Upon binding to HER3, patritumab deruxtecan undergoes receptor-mediated internalization and intracellular release of the DXd payload, resulting in DNA damage and apoptosis of tumor cells. Despite its therapeutic potential, the immunogenicity profile of this ADC, including the formation of anti-drug antibodies (ADAs) against the antibody moiety, the linker-payload complex, or neoantigenic epitopes, represents a critical parameter that can influence pharmacokinetics, safety, and clinical efficacy. The validated Patritumab Deruxtecan (ADC) ELISA Kit provides a standardized, quantitative analytical platform for the detection of anti-patritumab deruxtecan antibodies in human serum and plasma, supporting comprehensive immunogenicity assessment, pharmacokinetic correlation, and translational research in the field of ADC-based oncology therapy.
Figure 1. Overview of Accurate Quantification and Immunogenicity Monitoring for Patritumab Deruxtecan ADC with Validated ELISA Kits Characteristics.
Human epidermal growth factor receptor 3 (HER3, also known as ErbB3) is a member of the EGFR family that lacks intrinsic kinase activity but is capable of heterodimerization with other EGFR family members, particularly HER2, leading to potent activation of the PI3K/AKT and MAPK signaling pathways. HER3 is widely expressed in normal epithelial tissues, but its overexpression and aberrant signaling have been documented across multiple cancer types, including NSCLC, breast cancer, ovarian cancer, colorectal cancer, and head and neck squamous cell carcinoma. In the context of acquired resistance to EGFR-targeted tyrosine kinase inhibitors (TKIs), HER3 upregulation serves as a key adaptive mechanism that sustains tumor cell survival and proliferation. This dependency creates a compelling therapeutic vulnerability, making HER3 a high-value target for ADC development. Patritumab deruxtecan exploits this vulnerability by directing a potent cytotoxic payload specifically to HER3-overexpressing cells while sparing HER3-negative normal tissues, thereby broadening the therapeutic index compared to conventional chemotherapy. The clinical success of this ADC in heavily pretreated patient populations underscores the translational relevance of HER3-targeted strategies and reinforces the need for robust analytical tools to monitor both drug exposure and host immune responses to the ADC.
The pharmacological profile of patritumab deruxtecan is defined by its multicomponent structure: the anti-HER3 antibody provides target specificity and extended half-life, the cleavable linker ensures payload release in the tumor microenvironment, and the DXd payload exerts potent antitumor activity with a distinct mechanism of action from microtubule-targeting agents. While this modular architecture enables precise drug delivery, it also introduces multiple potential immunogenic determinants that can elicit anti-drug antibody responses. Anti-ADC antibodies may be directed against the antibody variable or constant regions, the peptide linker, the small-molecule payload, or conjugated epitopes formed at the linker-antibody junction. The clinical significance of ADA formation against patritumab deruxtecan includes accelerated clearance of the ADC, reduced tumor exposure, neutralization of target binding, infusion-related hypersensitivity reactions, and altered pharmacokinetic profiles that may necessitate dose adjustments. Systematic immunogenicity monitoring using validated assays is therefore essential in clinical trials and post-marketing studies to characterize the incidence, titer, and neutralizing capacity of anti-patritumab deruxtecan antibodies, and to correlate these immune responses with safety and efficacy endpoints. The Anti-Patritumab Deruxtecan ELISA Kit is specifically designed to address these analytical challenges, offering a sensitive and reproducible platform for the quantitative measurement of ADAs in human biological matrices.
The clinical development of patritumab deruxtecan has been driven by the unmet need for effective therapies in HER3-expressing solid tumors that have progressed on standard-of-care regimens. In the pivotal Phase 2 HERTHENA-Lung01 trial, patritumab deruxtecan demonstrated clinically meaningful and durable responses in patients with EGFR-mutated NSCLC who had previously received EGFR-TKI therapy, with an objective response rate of approximately 40% and a manageable safety profile characterized primarily by gastrointestinal and hematologic toxicities. In breast cancer, particularly in hormone receptor-positive/HER2-negative and triple-negative subtypes with HER3 expression, patritumab deruxtecan has shown encouraging antitumor activity as monotherapy and in combination with other agents, reflecting the broad expression of HER3 across breast cancer phenotypes. Additionally, exploratory studies have extended the clinical evaluation of this ADC to colorectal cancer, gastric cancer, and other solid tumors where HER3 plays a pathogenic role. The diverse clinical applications of patritumab deruxtecan create a wide range of patient populations in whom immunogenicity assessment is critical, as variations in baseline immune competence, prior treatment exposure, and tumor burden can influence the likelihood and magnitude of ADA formation. The Anti-Patritumab Deruxtecan ELISA Kit provides a standardized tool to support these diverse clinical research settings, enabling consistent data generation across trials and indications.
HER3-mediated signaling is predominantly transduced through the PI3K/AKT pathway, a central axis regulating cell survival, metabolism, and proliferation. Upon heterodimerization with HER2 or other EGFR family members, HER3 is phosphorylated at multiple intracellular tyrosine residues, which serve as docking sites for the p85 regulatory subunit of PI3K, leading to AKT activation and downstream phosphorylation of pro-survival effectors. Patritumab deruxtecan disrupts this pathway by binding to HER3 and promoting receptor internalization and degradation, while simultaneously delivering the DXd payload to induce DNA damage and apoptotic cell death. This dual mechanism—target pathway inhibition coupled with cytotoxic payload delivery—distinguishes patritumab deruxtecan from naked HER3 antibodies and contributes to its enhanced antitumor activity. Understanding the relationship between HER3 receptor density, ADC internalization efficiency, and intracellular payload release is essential for interpreting pharmacokinetic and pharmacodynamic data. The Anti-Patritumab Deruxtecan ELISA Kit supports these investigations by enabling quantitative assessment of ADA that may interfere with receptor binding or cellular uptake, thereby providing mechanistic insights into resistance mechanisms and treatment optimization strategies.
The Anti-Patritumab Deruxtecan (ADC) ELISA Kit is a quantitative sandwich immunoassay developed specifically for the detection and measurement of anti-patritumab deruxtecan antibodies in human serum and plasma samples, including both EDTA and heparin anticoagulated plasma. This assay employs a microplate coated with patritumab deruxtecan ADC to capture anti-ADC antibodies present in patient samples. Following an incubation and washing step, captured antibodies are detected using an HRP-conjugated secondary detection probe, and the signal is amplified through a TMB-based colorimetric reaction. The resulting absorbance is proportional to the concentration of anti-ADC antibodies in the sample, allowing quantitative determination via interpolation from a standard curve prepared from a reference standard. The kit is classified as a research use only (RUO) product, intended for preclinical and clinical research applications, and is not intended for diagnostic procedures or therapeutic decision-making in individual patients.
Key technical features of the Anti-Patritumab Deruxtecan ELISA Kit include:
The Anti-Patritumab Deruxtecan (ADC) ELISA Kit provides a validated, quantitative analytical platform for the detection of anti-patritumab deruxtecan antibodies in human serum and plasma, addressing the critical immunogenicity monitoring requirements associated with ADC therapy in HER3-positive malignancies. By enabling systematic screening and quantitative measurement of anti-ADC antibody responses, this assay kit supports the integration of immunogenicity data into pharmacokinetic-pharmacodynamic analysis, clinical trial safety evaluation, and post-marketing surveillance programs. As the therapeutic landscape for antibody-drug conjugates continues to expand with the development of novel target antigens, novel payloads, and optimized linker technologies, standardized immunogenicity assessment tools such as this ELISA kit will remain indispensable for ensuring the safe and effective clinical application of patritumab deruxtecan and its emerging biosimilar and next-generation counterparts. Together with complementary research resources targeting the HER3 receptor, EGFR family signaling, and ADC pharmacology, this validated assay system provides a comprehensive analytical infrastructure for researchers advancing the understanding and clinical development of ADC-based cancer therapeutics.
| Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Method | |
| DEIA-JY25385 | Patritumab deruxtecan (ADC) ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
| Target | Cat. No. | Product Name | Host | Isotype | Application | |
| ERBB3 | DMAB-CLS25241 | Human Anti-Human HER3-Dxd ADC [Patritumab deruxtecan] | Human | IgG | Reference Antibody | Inquiry |
| ERBB3 | CABT-CS395 | Human Anti-Human HER3 (patritumab biosimilar ) Monoclonal antibody, clone patritumab | Human | IgG1 | ELISA, FC | Inquiry |
Loading ......
